All In Biotech

Drug Trial Radar · NCT06143956

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Interventions for Chronic Weight Management in Adult Participants With Obesity or Overweight

Last checked: Nov 19, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 1,481 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,481

Planned (sponsor's estimate)

Start

Nov 17, 2023

Primary completion

Sep 2027

Study completion Feb 2028

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Nov 22, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Screening
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various investigational interventions for chronic weight management with intervention-specific appendices (ISAs). The CWMM establishes entry criteria for newly enrolled participants across the master and the ISAs. The ISAs may start independently of other ISAs as interventions become available for clinical testing. The results for the CWMM screening record will be reported when all the ISA's complete.

Conditions

  • Obesity
  • Overweight

Interventions

  • LY3305677Drug

    Administered SC. ISA specific interventions will be listed in the ISA.

  • LY3841136Drug

    Administered SC. ISA specific interventions will be listed in the ISA.

  • TirzepatideDrug

    Administered SC. ISA specific interventions will be listed in the ISA.

  • LY3549492Drug

    Administered orally. ISA specific interventions will be listed in the ISA.

  • LY3532226Drug

    Administered SC. ISA specific interventions will be listed in the ISA.

  • PlaceboDrug

    Administered SC. ISA specific interventions will be listed in the ISA.

  • PlaceboDrug

    Administered orally. ISA specific interventions will be listed in the ISA.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Allocated to Each ISATime frame: Baseline to Week 6

Locations

57 sites in 2 countries. Site status is shown where the registry gives one.

  • The Institute for Liver Health II dba Arizona Clinical Trials - Mesa

    Chandler, Arizona · Recruiting

  • HOPE Research Institute

    Phoenix, Arizona · Completed

  • Headlands Research - Scottsdale

    Scottsdale, Arizona · Recruiting

  • The Institute for Liver Health II dba Arizona Liver Health-Tucson

    Tucson, Arizona · Recruiting

  • NorCal Medical Research, Inc

    Greenbrae, California · Recruiting

  • Velocity Clinical Research, Huntington Park

    Huntington Park, California · Recruiting

  • Peninsula Research Associates

    Rolling Hills Estates, California · Recruiting

  • Diablo Clinical Research, Inc.

    Walnut Creek, California · Recruiting

  • Stamford Therapeutics Consortium

    Stamford, Connecticut · Recruiting

  • Northeast Research Institute (NERI)

    Fleming Island, Florida · Completed

  • New Horizon Research Center

    Miami, Florida · Recruiting

  • Indago Research & Health Center, Inc

    Miami Lakes, Florida · Recruiting

  • Suncoast Clinical Research, Inc.

    New Port Richey, Florida · Recruiting

  • Charter Research - Winter Park

    Orlando, Florida · Recruiting

  • Charter Research - Lady Lake

    The Villages, Florida · Recruiting

  • Pacific Diabetes & Endocrine Center

    Honolulu, Hawaii · Completed

  • Medical Research Partners

    Ammon, Idaho · Recruiting

  • Great Lakes Clinical Trials - Ravenswood

    Chicago, Illinois · Active not recruiting

  • Great Lakes Clinical Trials - Ravenswood

    Chicago, Illinois · Recruiting

  • NorthShore University Health System

    Skokie, Illinois · Completed

  • Iowa Diabetes and Endocrinology Research Center

    West Des Moines, Iowa · Recruiting

  • Cotton O'Neil Diabetes & Endocrinology

    Topeka, Kansas · Recruiting

  • Monroe Biomedical Research - Louisville

    Louisville, Kentucky · Recruiting

  • Knownwell

    Needham, Massachusetts · Recruiting

  • Lucida Clinical Trials

    New Bedford, Massachusetts · Recruiting

  • Headlands Research - Detroit

    Southfield, Michigan · Recruiting

  • Arcturus Healthcare , PLC, Troy Internal Medicine Research Division

    Troy, Michigan · Recruiting

  • StudyMetrix Research

    City of Saint Peters, Missouri · Recruiting

  • Clinvest Headlands Llc

    Springfield, Missouri · Recruiting

  • Las Vegas Medical Research

    Las Vegas, Nevada · Recruiting

  • Dent Neurologic Institute

    Amherst, New York · Recruiting

  • Velocity Clinical Research, Syracuse

    East Syracuse, New York · Recruiting

  • North Suffolk Neurology

    Port Jefferson Station, New York · Completed

  • Rochester Clinical Research, LLC

    Rochester, New York · Recruiting

  • Medication Management

    Greensboro, North Carolina · Recruiting

  • Monroe Biomedical Research

    Monroe, North Carolina · Recruiting

  • Lucas Research, Inc

    Morehead City, North Carolina · Recruiting

  • Lucas Research, Inc.

    New Bern, North Carolina · Recruiting

  • CTI Clinical Research Center

    Cincinnati, Ohio · Recruiting

  • Tribe Clinical Research, LLC

    Greenville, South Carolina · Recruiting

Showing 40 of 57 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.